Organotypic intestinal culture and methods of use thereof

• US 7,217,570 B2
• Filed: 08/22/2002
• Issued: 05/15/2007
• Est. Priority Date: 08/23/2001
• Status: Expired due to Fees

• Current Assignee: The Wistar Institute of Anatomy & Biology (University of Pennsylvania)
• Original Assignee: The Wistar Institute
• Inventors: Herlyn, Meenhard, Kalabis, Jiri
• Primary Examiner(s): CHEN, SHIN LIN
• Application Number:
  US10/485,283
• Publication Number:
  US 20040175367A1
• Time in Patent Office: 1,727 Days
• Field of Search: 435/371, 435/373, 435/384, 435/395, 435/397, 623/23.72, 623/23.75
• US Class Current: 435/397
• CPC Class Codes: A61K 35/38 Stomach; Intestine; Goblet cells; Oral mucosa; Saliva
• CPC Class Codes: C12N 2500/25 Insulin-transferrin; Insulin-transferrin-selenium
• CPC Class Codes: C12N 2501/105 Insulin-like growth factors [IGF]
• CPC Class Codes: C12N 2501/11 Epidermal growth factor [EGF]
• CPC Class Codes: C12N 2501/12 Hepatocyte growth factor [HGF]
• CPC Class Codes: C12N 2501/125 Stem cell factor [SCF], c-kit ligand [KL]
• CPC Class Codes: C12N 2501/365 Endothelin
• CPC Class Codes: C12N 2502/1323 Adult fibroblasts
• CPC Class Codes: C12N 2502/1347 Smooth muscle cells
• CPC Class Codes: C12N 2502/23 Gastro-intestinal tract cells
• CPC Class Codes: C12N 5/0697 Artificial constructs associating cells of different lineages, e.g. tissue equivalents blood vessels C12N5/0691
• CPC Class Codes: G01N 2333/485 Epidermal growth factor [EGF] (urogastrone)
• CPC Class Codes: G01N 33/5082 Supracellular entities, e.g. tissue, organisms

Abstract

An organotypic culture comprises an artificial stroma overlayed with epithelial cells isolated from a human colon or intestine. The stroma comprises a mixture of collagen and human fibroblasts isolated from a human colon or intestine. The culture contains a factor that binds the IGF-1 receptor, a factor that binds the EGF receptor, and a factor that binds the LIF receptor. These factors may be added exogenously to the culture via medium or may be expressed by various recombinantly engineered cell types in the culture. The organotypic culture can result in growth that is in situ-like or emphasizes other physiological or morphological states, depending on the balance of factors in the growth media. The organotypic culture may be used in methods for screening of therapeutic, carcinogenic, or growth enhancement factors, or for treating intestinal injuries by applying to the site of an injury the intact culture or the components thereof.

Claims

1. An organotypic culture comprising an artificial stroma comprising a mixture of collagen and human fibroblasts isolated from a human colon or intestine, said stroma overlayed with epithelial cells isolated from fetal human colon, wherein said culture contains a growth factor that binds the insulin growth factor-1 (IGF-1) receptor selected from insulin and IGF-1, a growth factor that binds the epidermal growth factor (EGF) receptor selected from EGF and tumor growth factor-alpha (TGF-alpha), and the growth factor leukemia inhibitory factor (LIF), which binds the LIF receptor.

2. The culture according to claim 1, wherein said collagen is selected from the group consisting of human collagen type I and bovine collagen type I.

3. The culture according to claim 1, wherein said fibroblasts are selected from the group consisting of adult human colon fibroblasts, fetal human colon fibroblasts, adult human small intestinal fibroblasts, fetal human small intestinal fibroblasts, and human fibroblast stem cells.

4. The culture according to claim 3, wherein said stem cells are isolated from human bone marrow.

5. The culture according to claim 1, further comprising human smooth muscle cells embedded into said collagen.

6. The culture according to claim 1, further comprising a layer of endothelial cells underlying said collagen and fibroblast mixture.

7. The culture according to claim 1, comprising at least one matrix protein selected from the group consisting of Laminin-1 and Laminin-2.

10. A method of preparing an organotypic culture of claim 1 comprising:

(a) assembling an artificial stroma by mixing collagen and fibroblasts;

(b) seeding said artificial stroma with epithelial cells isolated from fetal human colon in the presence of a growth factor that binds the IGF-1 receptor selected from insulin and IGF-1, a growth factor that binds the EGF receptor selected from EGF and tumor growth factor-alpha (TGF-alpha), and the growth factor LIF, which binds the LIF receptor.

11. The method according to claim 10, wherein said collagen is selected from the group consisting of human collagen type I and bovine collagen type I.

12. The method according to claim 10, wherein said fibroblasts are selected from the group consisting of adult human colon fibroblasts, fetal human colon fibroblasts, adult human small intestinal fibroblasts, fetal human small intestinal fibroblasts, and human fibroblast stem cells.

13. The method according to claim 12, wherein said stein cells are isolated from human bone marrow.

14. The method according to claim 10, further comprising mixing human smooth muscle cells into said collagen mixture.

15. The method according to claim 10, further comprising layering said artificial stroma over a layer of endothelial cells.

16. The method according to claim 10, comprising introducing at least one matrix protein selected from the group consisting of Laminin-1 and Laminin-2 between said artificial stroma and said epithelial cells or overlaying said epithelial cells.

17. The method according to claim 10, wherein said culture further comprises one or more of a factor selected from the group consisting of endothelin-3, hepatocyte growth factor, stem cell factor and antocrine motility faetor.

18. The method according to claim 10, wherein said culture further comprises an additional component selected from the group consisting of transferrin, fetal calf serum and combinations thereof.

19. The method according to claim 10, further comprising seeding a malignant cell on the artificial stroma to create a model of tumor formation or tumor-stroma interaction.

8. An organotypic culture comprising an artificial stroma comprising a mixture of collagen and human fibroblasts isolated from a human colon or intestine, said stroma overlayed with epithelial cells isolated from fetal human colon, wherein said culture contains a growth factor that binds the IGF-1 receptor selected from insulin and IGF-1, a growth factor that binds the EGF receptor selected from EGF and tumor growth factor-alpha (TGF-alpha), the growth factor LIF, which binds the LIF receptor, the growth factor endothelin-3 (ET-3), which binds the ET-3 receptor, a growth factor that binds the hepatocyte growth factor (HGF) receptor selected from HGF and tumor growth factor-beta (TGF-beta), the growth factor stem cell factor (SCF), which binds the SCF receptor, and the growth factor autocrine motility factor (AMF), which binds the AMF receptor.

9. The culture according to claim 8, further comprising an additional component selected from the group consisting of transferrin, fetal calf serum, and combinations thereof.